Drugs / FavId™
FavId™
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 23 trials | ||||||
| Phase 2 | NCT00104819 | Sep 2004 → Jun 2011 | lymphoma | Favrille | Terminated | No outcome recorded |
| Phase 2 | NCT00258336 | Aug 2004 → Nov 2009 | lymphoma | Favrille | Unknown | No outcome recorded |
| Phase 2 | NCT00036426 | Mar 2001 → ? | indolent B-cell non-Hodgkin lymphoma | Favrille | Unknown | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT00324831 | — | lymphoma | Favrille | Suspended | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FavId | “Phase II Trial of FavId™ (Patient-Specific Idiotype/KLH) and GM-CSF in Subjects Who Demonstrated Progressive Disease and Did Not Receive FavId on Study FavId-06” NCT00104819 ↗3“autologous immunoglobulin idiotype-KLH conjugate vaccine (FavId™) subcutaneously (SC) once on day 1” NCT00258336 ↗ “autologous immunoglobulin idiotype-KLH conjugate vaccine (FavId®)” NCT00324831 ↗ |
| Known as | autologous immunoglobulin idiotype-KLH conjugate vaccine | “Provide treatment with autologous immunoglobulin idiotype-KLH conjugate vaccine (FavId)™ and sargramostim (GM-CSF) to patients with progressive grade 1, 2, or 3 follicular...” NCT00104819 ↗ |
| Known as | Id-KLH | “FavId (Id-KLH) active immunotherapy” NCT00036426 ↗ |
| Modality | Vaccine | “The purpose of this study was to determine if an idiotype vaccine, made from a patient's lymphoma that has returned after chemotherapy and/or rituximab, would be able to shrink...” NCT00036426 ↗ |
| Route | Subcutaneous | “vaccine (FavId™) subcutaneously (SC) once on day 1” NCT00258336 ↗ |